Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLPG0187 · 1 trial · 1 indication
Patients will be monitored for cardiovascular safety (ECG) and adverse events, and blood- and urine-samples taken before and at fixed timepoints after a one-hour infusion of GLPG0187; if patients tolerate the treatment well, procedures will be repeated before and at fixed timepoints after the start of a three-week continuous infusion patients. Through monitoring and analysis of the blood- and urine-samples, it will be established whether the study medication would have any negative effects on the patient's general condition. Results will indicate whether DLT has occurred.
| Arm | Type | Description |
|---|---|---|
| GLPG0187 | EXPERIMENTAL | GLPG0187 for infusion |
| Name | Type | Description |
|---|---|---|
| GLPG0187 | DRUG | continuous IV infusion |
Inclusion Criteria: * Pathologically confirmed diagnosis of advanced, recurrent, or metastatic cancer who are refractory to standard therapy or for whom no standard therapy exist. * Age of 18 years or older. * Measurable (according to RECIST 1.1) and evaluable disease as determined by the Investiga...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GLPG0187 is an investigational small molecule developed for the treatment of solid tumors. It has been studied in a Phase 1 clinical trial in patients with solid tumors, and it is not approved for any indication. Lakefront Biotherapeutics is developing the drug.
GLPG0187 is being developed by Lakefront Biotherapeutics, which trades under the ticker LKFT. The company is responsible for the clinical development of the drug, including the completed Phase 1 trial in patients with solid tumors.
GLPG0187 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any use.
GLPG0187 has been evaluated in one clinical trial: NCT01313598, titled "GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors." This Phase 1 trial enrolled 20 patients in the Netherlands and is now completed.
No, GLPG0187 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for solid tumors. Approval has not been granted, and further clinical development would be required before any regulatory submission.